AveXis (NASDAQ:AVXS) received a $120.00 target price from Morgan Stanley in a report released on Friday. The brokerage presently has a “buy” rating on the stock. Morgan Stanley’s price target suggests a potential upside of 17.55% from the stock’s previous close.

Several other equities research analysts have also recently issued reports on the stock. Zacks Investment Research cut shares of AveXis from a “buy” rating to a “hold” rating in a research report on Monday, October 30th. Bank of America reduced their price objective on shares of AveXis from $115.00 to $112.00 and set a “buy” rating on the stock in a research report on Friday, November 10th. Canaccord Genuity started coverage on shares of AveXis in a research report on Thursday, October 26th. They set a “hold” rating and a $110.00 price objective on the stock. Wells Fargo & Co reissued an “outperform” rating on shares of AveXis in a report on Friday, September 29th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $130.00 price objective (up from $123.00) on shares of AveXis in a research note on Thursday, October 12th. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and thirteen have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $111.94.

AveXis (AVXS) traded down $2.66 during midday trading on Friday, reaching $102.08. 837,632 shares of the company’s stock were exchanged, compared to its average volume of 367,840. AveXis has a 12 month low of $50.56 and a 12 month high of $116.15.

AveXis (NASDAQ:AVXS) last released its earnings results on Thursday, November 9th. The company reported ($1.52) EPS for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.04). During the same period in the prior year, the company posted ($0.87) EPS. equities analysts forecast that AveXis will post -6.23 earnings per share for the current year.

In related news, insider Brian K. Kaspar sold 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $109.75, for a total value of $1,646,250.00. Following the sale, the insider now owns 1,808,386 shares in the company, valued at $198,470,363.50. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Andrew F. Knudten sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $94.48, for a total value of $188,960.00. Following the completion of the sale, the vice president now owns 7,000 shares in the company, valued at approximately $661,360. The disclosure for this sale can be found here. Insiders sold 67,340 shares of company stock valued at $6,840,745 over the last quarter. 18.60% of the stock is currently owned by corporate insiders.

Institutional investors have recently added to or reduced their stakes in the business. Janus Henderson Group PLC acquired a new position in shares of AveXis during the 2nd quarter worth approximately $55,439,000. BlackRock Inc. raised its stake in shares of AveXis by 34.7% during the 2nd quarter. BlackRock Inc. now owns 2,301,229 shares of the company’s stock worth $189,069,000 after buying an additional 592,843 shares during the period. Alliancebernstein L.P. raised its stake in shares of AveXis by 4,448.8% during the 2nd quarter. Alliancebernstein L.P. now owns 564,966 shares of the company’s stock worth $46,418,000 after buying an additional 552,546 shares during the period. FMR LLC raised its stake in shares of AveXis by 13.1% during the 2nd quarter. FMR LLC now owns 4,705,433 shares of the company’s stock worth $386,598,000 after buying an additional 544,475 shares during the period. Finally, State Street Corp raised its stake in shares of AveXis by 104.2% during the 2nd quarter. State Street Corp now owns 1,000,001 shares of the company’s stock worth $82,163,000 after buying an additional 510,189 shares during the period. Institutional investors and hedge funds own 92.88% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Morgan Stanley Reiterates “$120.00” Price Target for AveXis (AVXS)” was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://www.watchlistnews.com/morgan-stanley-reiterates-120-00-price-target-for-avexis-avxs/1797956.html.

About AveXis

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Analyst Recommendations for AveXis (NASDAQ:AVXS)

Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with Analyst Ratings Network's FREE daily email newsletter.